Polyethersulfone Dialyzer Market Size, Share and Global Trend By Product Type (Low Permeability Polyethersulfone Dialyzer, High Permeability Polyethersulfone Dialyzer), By Disease Indication (Chronic Kidney Diseases, End-stage Renal Diseases, Diabetes, Hypertension, Renal Failure), By End User (Hospitals, Diagnostic Centers, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare), and Regional Forecast, 2024-2032

The surge in chronic kidney diseases and end-stage renal disease (ESRD), is augmenting the demand for blood purification interventions in the healthcare environment. According to the National Chronic Kidney Disease Fact Sheet, in 2017, nearly 30 million U.S. population was estimated to have chronic kidney disease (CKD), which accounted for 15% of the U.S. population. Haemodialysis is a common treatment for patients with chronic kidney diseases (CKD), end-stage renal disease (ESRD), renal failure, and others.

One of the important component required for hemodialysis is dialyzer. Polyethersulfone is being used as a synthetic dialyzer membrane for over a decade. Polyethersulfone dialyzer is characterized by an improved permeability due to the presence of comparatively more homogenous and dense pore size. The growing numbers of dialysis centers providing round the clock services are further helping the global polyethersulfone dialyzer market to flourish. Moreover, the launch of 4008A dialysis machine by Fresenius Medical Care AG & Co. KGaA in January 2019 is expected to improve access to dialysis treatment to end-stage renal disease.

Primary reasons attributed to the growth in global polyethersulfone dialyzer market are the rising demand for hemodialysis, rapid adoption of hollow membrane for the manufacture of dialyzers, and health reimbursement facilities for dialysis. Also, the surge in homecare dialysis services is expected to fuel the global polyethersulfone dialyzer market during the anticipated period.

However, the presences of other competitive products such as polycarbonate dialyzer, polymethylmethacrylate dialyzer and others are expected to hamper the growth in polyethersulfone dialyzer market.

Key Players Covered

Some of the major companies that are present in the global polyethersulfone dialyzer market are Baxter, Fresenius Medical Care Asia Pacific Limited, NxStage Medical, Inc., Farmasol, Medica S.p.A., Dialife Group, NIPRO, Serumwerk Bernburg AG, Asahi Kasei Medical Co. Ltd. and, other players.

SEGMENTATION

The chronic kidney disease segment is expected to have a major portion of the global polyethersulfone dialyzer market in the forecast duration owing to a greater prevalence of chronic kidney diseases and increased government initiatives such as Kidney Disease Outcomes Quality Initiative.

Key Insights

• Prevalence of Diabetes and Kidney Disease – For Key Countries
• The regulatory scenario for key countries
• Reimbursement Scenario for key countries
• Pricing Analysis
• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

In North America, the polyethersulfone dialyzer market is anticipated to witness fast growth during the forecast period due to properly planned health reimbursement for dialysis. As per the U.S. Renal Data System Report by National Institute of Diabetes and Kidney Diseases, in 2015, Taiwan, the Jalisco of Mexica and the United States were reported to have the highest incidence of end-stage renal disease (ESRD) with rates of 476, 411, and 378 patients per million populations which serves as a growth factor for polyethersulfone dialyzer market in North America and Asia Pacific. The polyethersulfone dialyzer market in Europe is projected to expand in the forecast duration owing to the rising prevalence of kidney diseases and active government interventions.

Key Industry Developments

• In January 2019, Fresenius Medical Care AG & Co. KGaA launched 4008A dialysis machine with the aim to improve access to dialysis treatment to end-stage renal disease patients.
• In August 2017, B. Braun Melsungen AG received FDA clearance for its haemodialyzer product named Diacap Pro for use in dialysis patients.
• In September 2016, B. Braun Melsungen AG launched Xevonta, an innovative dialyzer in the U.S. market to filter the blood.
• In 2015, National Kidney Foundation published an update of the KDOQI Clinical Practice Guideline for Haemodialysis Adequacy, in order to ensure improved care for patients